Trials / Completed
CompletedNCT05677958
Protein Intake in Patients With Colorectal or Lung Cancer When Receiving a Nutritional Supplement
Protein Intake in Patients With Colorectal or Lung Cancer During First Line Treatment With Chemo (Radio) - or Immunotherapy When Receiving a Low Volume, Energy Dense and High Protein Oral Nutritional Supplement: a Randomized, Controlled Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Nutricia Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The PROTEOS study is an randomized controlled, open label, parallel-group, multi-centre and multicounty interventional study to assess the acceptance and implementation of Compact Protein, a low volume, energy dense and high protein oral nutritional support in clinical practice according to the ESPEN guidelines in colorectal and lung cancer patients undergoing chemo(radio)- or immunotherapy treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | 125 mL Fortimel/Nutridrink Compact Protein | 125 mL Fortimel/Nutridrink Compact Protein®\* two servings per day (300 kcal, 18 g protein per serving). |
Timeline
- Start date
- 2019-01-17
- Primary completion
- 2021-12-17
- Completion
- 2021-12-17
- First posted
- 2023-01-10
- Last updated
- 2023-01-10
Locations
14 sites across 7 countries: Belgium, Estonia, Lithuania, Netherlands, Norway, Poland, Portugal
Source: ClinicalTrials.gov record NCT05677958. Inclusion in this directory is not an endorsement.